Top

Published in:

01-08-2017 | PRECLINICAL STUDIES

Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft

Authors: Nataly Tarasenko, Abraham Nudelman, Gabriela Rozic, Suzanne M. Cutts, Ada Rephaeli

Published in: Investigational New Drugs | Issue 4/2017

Summary

The histone deacetylase (HDAC) inhibitory prodrugs of butyric (AN7) and valproic (AN446) acids, which release the active acids upon metabolic degradation, were studied examining their differential effects on the viability, HDAC inhibitory activity and the DNA damage response (DDR), in glioblastoma cell and normal human astrocytes (NHAs). In xenografts of glioblastoma, AN7 or AN446 given or the combination of each of them with Dox augmented the anticancer activity of Dox and protected the heart from its toxicity. In order to determine the processes underlying these opposing effects, the changes induced by these treatments on the epigenetic landscape, the DDR, and fibrosis were compared in tumors and hearts of glioblastoma xenografts. The potency of AN7 and AN446 as HDAC inhibitors was correlated with their effects on the viability of the cancer and non-cancer cells. The prodrugs affected the epigenetic landscape and the DDR in a tissue-specific and context-dependent manner. Findings suggest that the selectivity of the prodrugs could be attributed to their different effects on histone modification patterns in normal vs. transformed tissues. Further studies are warranted to substantiate the potential of AN446 as a new anticancer drug for glioblastoma patients.

de Ruijter AJM, van Gennip AH, Caron HN et al (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737–749. doi:10.1042/BJ20021321 CrossRefPubMedPubMedCentral

Mottet D, Castronovo V (2008) Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25:183–189. doi:10.1007/s10585-007-9131-5 CrossRefPubMed

Weichert W (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280:168–176. doi:10.1016/j.canlet.2008.10.047 CrossRefPubMed

Choudhary C, Kumar C, Gnad F et al (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325:834–840. doi:10.1126/science.1175371 CrossRefPubMed

Unnikrishnan A, Gafken PR, Tsukiyama T (2010) Dynamic changes in histone acetylation regulate origins of DNA replication. Nat Struct Mol Biol 17:430–437. doi:10.1038/nsmb.1780 CrossRefPubMedPubMedCentral

Zhang Y, Reinberg D (2001) Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 15:2343–2360. doi:10.1101/gad.927301 CrossRefPubMed

Gryder BE, Sodji QH, Oyelere AK (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 4:505–524. doi:10.4155/fmc.12.3 CrossRefPubMedPubMedCentral

Mottamal M, Zheng S, Huang TL, Wang G (2015) Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20:3898–3941. doi:10.3390/molecules20033898 CrossRefPubMedPubMedCentral

Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958–3969. doi:10.1158/1078-0432.CCR-08-2785 CrossRefPubMed

10.

Entin-Meer M, Yang X, VandenBerg SR et al (2007) In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-Oncology 9:82–88. doi:10.1215/15228517-2006-032 CrossRefPubMedPubMedCentral

11.

Patnaik A, Rowinsky EK, Villalona MA et al (2002) A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res 8:2142–2148

12.

Reid T, Valone F, Lipera W et al (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate ( Pivanex , AN-9 ) in advanced non-small cell lung cancer. Lung Cancer 45:381–386. doi:10.1016/j.lungcan.2004.03.002 CrossRefPubMed

13.

Rephaeli A, Entin-Meer M, Angel D et al (2006) The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Investig New Drugs 24:383–392. doi:10.1007/s10637-006-6213-1 CrossRef

14.

Tarasenko N, Kessler-Icekson G, Boer P et al (2012a) The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Investig New Drugs 30:130–143. doi:10.1007/s10637-010-9542-z CrossRef

15.

Tarasenko N, Cutts SM, Phillips DR et al (2012b) Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor. PLoS One 7:e31393. doi:10.1371/journal.pone.0031393 CrossRefPubMedPubMedCentral

16.

Tarasenko N, Nudelman A, Tarasenko I et al (2008) Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin Exp Metastasis 25:703–716. doi:10.1007/s10585-008-9179-x CrossRefPubMed

17.

Tarasenko N, Cutts SM, Phillips DR et al (2014) A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo. Biochem Pharmacol 88:158–168. doi:10.1016/j.bcp.2014.01.023 CrossRefPubMed

18.

Krauze AV, Myrehaug SD, Chang MG et al (2015) A phase 2 study of concurrent radiation therapy, Temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys 92:986–992. doi:10.1016/j.ijrobp.2015.04.038 CrossRefPubMedPubMedCentral

19.

Felix FHC, De Araujo OL, Da Trindade KM et al (2014) Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center. J Neuro-Oncol 116:261–266. doi:10.1007/s11060-013-1280-6 CrossRef

20.

Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist 19:751–759. doi:10.1634/theoncologist.2014-0060 CrossRefPubMedPubMedCentral

21.

Yuan Y, Xiang W, Qing M et al (2014) Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review. Seizure 23:830–835. doi:10.1016/j.seizure.2014.06.015 CrossRefPubMed

22.

Fay MF, Head R, Sminia P et al (2016) Valproate in Adjuvant Glioblastoma Treatment. J Clin Oncol 34:3105–3107. doi:10.1200/JCO.2016.67.2162 CrossRefPubMed

23.

Felix F, Fontenele J (2016) Valproic acid may Be tested in patients with H3F3A-mutated high-grade gliomas. J Clin Oncol 34:3104–3105. doi:10.1200/JCO.2016.67.1073 CrossRefPubMed

24.

Happold C, Gorlia T, Chinot O et al (2016) Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol 34:731–739. doi:10.1200/JCO.2015.63.6563 CrossRefPubMedPubMedCentral

25.

Nudelman A, Gnizi E, Katz Y et al (2001) Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur J Med Chem 36:63–74. doi:10.1016/S0223-5234(00)01199-5 CrossRefPubMed

26.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and. Methods 25:402–408. doi:10.1006/meth.2001.1262 CrossRefPubMed

27.

Engel D, Nudelman A, Levovich I et al (2006) Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines. J Cancer Res Clin Oncol 132:673–683. doi:10.1007/s00432-006-0116-6 CrossRefPubMed

28.

Chou T-CC (2010) Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res 70:440–446. doi:10.1158/0008-5472.CAN-09-1947 CrossRefPubMed

29.

Kumar R, Wang RA (2016) Structure, expression and functions of MTA genes. Gene 582:112–121. doi:10.1016/j.gene.2016.02.012 CrossRefPubMedPubMedCentral

30.

Millard CJ, Varma N, Saleh A et al (2016) The structure of the core NuRD repression complex provides insights into its interaction with chromatin. Elife 5:1–21. doi:10.7554/eLife.13941 CrossRef

31.

Patel DJ (2016) A structural perspective on readout of epigenetic histone and DNA methylation marks. Cold Spring Harb Perspect Biol 8:a018754. doi:10.1101/cshperspect.a018754 CrossRefPubMed

32.

Kinner A, Wu W, Staudt C, Iliakis G (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36:5678–5694. doi:10.1093/nar/gkn550 CrossRefPubMedPubMedCentral

33.

Bose P, Dai Y, Grant S (2014) Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143:323–336. doi:10.1016/j.pharmthera.2014.04.004 CrossRefPubMedPubMedCentral

34.

Beyer S, von Bueren AO, Klautke G, Guckenberger M (2016) A systematic review on the characteristics , treatments and outcomes of the patients with primary spinal glioblastomas or gliosarcomas reported in literature until March 2015. PLoS One 11:e0148312. doi:10.1371/journal.pone.0148312 CrossRefPubMedPubMedCentral

35.

Kramer OH, Zhu P, Ostendorff HP et al (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22:3411–3420. doi:10.1093/emboj/cdg315 CrossRefPubMedPubMedCentral

36.

Bhaskara S (2015) Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers. Cell Cycle 14:1779–1785. doi:10.1080/15384101.2015.1042634 CrossRefPubMedPubMedCentral

37.

Barry SP, Davidson SM, Townsend PA (2008) Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40:2023–2039. doi:10.1016/j.biocel.2008.02.020 CrossRefPubMed

38.

Laugesen A, Helin K (2014) Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 14:735–751. doi:10.1016/j.stem.2014.05.006 CrossRefPubMed

39.

Toh Y, Nicolson GL (2009) The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis 26:215–227. doi:10.1007/s10585-008-9233-8 CrossRefPubMed

40.

Hann SR (2014) MYC cofactors: molecular switches controlling diverse biological outcomes. Cold Spring Harb Perspect Med 4:a014399. doi:10.1101/cshperspect.a014399 CrossRefPubMedPubMedCentral

41.

Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE (2010) Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res 70:8319–8328. doi:10.1158/0008-5472.CAN-10-1136 CrossRefPubMed

42.

Thiery JP, Acloque H, Huang RYJ, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890. doi:10.1016/j.cell.2009.11.007 CrossRefPubMed

43.

Ho CY, López B, Coelho-Filho OR et al (2010) Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363:552–563. doi:10.1056/NEJMoa1002659 CrossRefPubMedPubMedCentral

44.

New M, Olzscha H, La Thangue NB (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 6:637–656. doi:10.1016/j.molonc.2012.09.003 CrossRefPubMed

45.

Füllgrabe J, Kavanagh E, Joseph B (2011) Histone onco-modifications. Oncogene 30:3391–3403. doi:10.1038/onc.2011.121 CrossRefPubMed

46.

Yu Y, Song C, Zhang Q et al (2012) Histone H3 lysine 56 methylation regulates DNA replication through its interaction with PCNA. Mol Cell 46:7–17. doi:10.1016/j.molcel.2012.01.019 CrossRefPubMedPubMedCentral

47.

Vempati RK, Jayani RS, Notani D et al (2010) p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage response in mammals. J Biol Chem 285:28553–28564. doi:10.1074/jbc.M110.149393 CrossRefPubMedPubMedCentral

48.

Luciano P, Dehé PM, Audebert S et al (2015) Replisome function during replicative stress is modulated by histone H3 lysine 56 acetylation through Ctf4. Genetics 199:1047–1063. doi:10.1534/genetics.114.173856 CrossRefPubMedPubMedCentral

49.

Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286–298. doi:10.1038/nrg2005 CrossRefPubMed

Title: Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft
Authors: Nataly Tarasenko
Abraham Nudelman
Gabriela Rozic
Suzanne M. Cutts
Ada Rephaeli
Publication date: 01-08-2017
Publisher: Springer US
Published in: Investigational New Drugs / Issue 4/2017
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-017-0448-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2017

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors

Lung cancer and β-glucans: review of potential therapeutic applications

Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer

Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer